Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25810853 | 0.86 | ATF4 (0.40) | RXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL22628186 | 0.82 | RXFP1 (0.54) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22627631 | 0.82 | MEN1 (0.54) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22627747 | 0.82 | RXFP1 (0.54) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22627924 | 0.81 | RXFP1 (0.53) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22628316 | 0.81 | RXFP1 (0.52) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL20999332 | 0.81 | HPGD (0.64) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22628204 | 0.80 | RXFP1 (0.52) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22628214 | 0.80 | MEN1 (0.52) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22627875 | 0.79 | HPGD (0.47) | RXFP1MEN1KMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | RXFP1 2368/4885MEN1 4714/4885KMT2A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.